pretickt

When does Alnylam report earnings?

Alnylam Pharmaceuticals, Inc. · end-of-day data as of Nov 13, 2026

Alnylam
ALNY · $22.11B
$165.04+5.4%
Nov 13, 2026 · close
$150$200$250SepOctNov9:3016:003 months -27.8%Nov 13 · close
▲ 6
  • PT$352.61 +113.7%
  • ConsensusBuy · 31
  • P/E vs own-89.5%
  • P/E vs sector-74.1%
  • Insiders$144K
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • P/E8.3x
  • RSI35
  • Resistance+34.9%
  • Off 52w high-65.6%
  • Volume1.1x
  • Bollingerlower half
  • News0.00
  • FCF yield+2.3%
  • 52w range$149–$480
  • ATR+6.4%
  • Off ATH-66.7%
▼ 3
  • Trendbearish
  • MAs0 of 4
  • MACD-0.89

Updates with the 15-min delayed price. Not a forecast or investment advice.

Alnylam ALNY reports its next earnings on Thursday, Feb 11, 2027, before the open, an estimated date the company has not confirmed yet. Analysts expect EPS of $1.72 on revenue of $1.53B. Alnylam beat the EPS estimate in 5 of its last 8 reports, and the stock moved ±10.8% on average the session after. The last report, on Oct 29, 2026: EPS of $16.26 against $1.66 expected and revenue of $1.46B against $1.43B; the stock fell 25.1% the next session.

The stock around its reports

⇔⇕$174$272$371$469Nov 24Apr 25Sep 25Feb 26Jul 26Dec 26AEAEEAEEAAEEAEAAE

Last close $165.04 · -41.0% over 2y · E earnings · D dividend · S split · A analyst rating change

Quarterly results

Q3 FY2026: Revenue +16.7% year over year, free cash flow 18.6% of revenue, operating margin 23.7%.

RevenueFree cash flow
Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Q3 FY2026Sep 30, 2026$1.46B15.72$271M75.2%23.7%148.6%
Q2 FY2026Jun 30, 2026$1.29B1.20$40.64M76.9%17.9%12.7%
Q1 FY2026Mar 31, 2026$1.17B1.51$48.67M81.9%23.0%17.6%
Q4 FY2025Dec 31, 2025$1.1B1.37$140M75.6%12.0%17.0%
Q3 FY2025Sep 30, 2025$1.25B1.84$313M84.2%29.5%20.1%
Q2 FY2025Jun 30, 2025$774M-0.51$139M81.5%-2.1%-8.6%
Q1 FY2025Mar 31, 2025$594M-0.44-$127M88.0%3.0%-9.7%
Q4 FY2024Dec 31, 2024$593M-0.65-$104M82.7%-17.7%-14.1%